-+ 0.00%
-+ 0.00%
-+ 0.00%

Alterity Therapeutics Receives Positive Regulatory Feedback Following Type C Meeting With FDA Regarding Planned Phase 3 Development Program For ATH434 In MSA

Benzinga·03/30/2026 11:26:23
Listen to the news

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA).

The Type C Meeting is part of a multidisciplinary strategy to seek alignment with the FDA on readiness to initiate a Phase 3 pivotal trial in MSA. Alterity received written feedback supporting its plans related to the clinical pharmacology and non-clinical development elements of the program.